Objective: We analysed nm23, c-erbB-2 and p53 protein expression in lung adenocarcinoma in relation to clinicopathological status and patient survival, to elucidate any potential prognostic value. Published reports suggest that high p53 and c-erbB-2 protein expression and loss of nm23 protein expression are associated with poor prognosis. Methods: A total of 162 pulmonary adenocarcinomas resected between 1980 and 1991 were stained using monoclonal antibodies to nm23 (NCL-nm23), c-erbB-2 (NCL-CB11) and p53 (DAKO Do7). Antigen retrieval was by microwave heating and bound antibody was visualised using standard immunohistochemical methods. Staining was scored by two observers blinded to tumour status and patient survival. Results: Of the tumours, 101/162 (62.3%) exhibited high-level p53 expression, 30 (18.5%) showed high-level c-erbB-2 membrane staining, and 77 (47.5%) demonstrated loss of nm23 positivity. The influence of T and N status and disease stage on postoperative survival was as expected. The predicted effect on patient survival of nm23, c-erbB-2 or nm23 protein expression suggested by previous studies was not verified by our work. This was true both overall and for groups within the same T or N status or stage. Conclusion: Immunohistochemical assessment of the nm23, c-erbB-2 and p53 proteins using the above monoclonal antibodies does not have value as an independent prognostic indicator in pulmonary adenocarcinoma. © 1997 Elsevier Science B.V.
Introduction
Lung cancer is the most common cause of cancer death in Scotland and pulmonary adenocarcinoma accounts for at least 20% of those lung cancers. The best chance for cure is still surgical resection of the tumour; however, the mortality rate remains consistently high, often because of the presence of occult metastasis at the time of operation. This disease is known to exhibit a varied range of clinical behaviour, with many tumours seeming to possess an inherent tendency towards metastasis, the major factor determining morbidity and mortality.
Numerous oncogene products have been highlighted as possible markers of prognosis in lung cancer, perhaps giving clinicians the ability to identify those patients who at, or even before, surgery may already have occult metastasis, which will determine the length of the patients' post-operative survival.
NME1 and NME2, the human analogues of the murine metastasis suppressor gene nm23 [17] , encode for the proteins NDPK-A and NDPK-B, respectively [15] . Although the precise roles of these proteins are not yet fully understood, they have been implicated in several fundamental cellular processes, e.g. G-proteinmediated signal transduction and microtubule assembly and disassembly [11] . Isotype specific studies have shown loss of NME1, at least in breast adenocar-cinoma, to be most closely associated with metastasis. Investigation of nm23 expression has yielded conflicting results, e.g. low levels of NDPK-B mRNA were associated with lymph node metastasis and poorer patient prognosis in gastric adenocarcinoma [9] , whereas in squamous carcinoma of the lung, high levels of NDPK-A mRNA were associated with advanced tumour stage [1] .
More consistent results have been shown regarding the oncogene c-erbB-2/p 185, with overexpression present in approximately 30% of lung adenocarcinomas [8, 18] Increased expression has been positively correlated with stage and shown to identify a subset of patients with poorer prognosis and shortened survival [18] .
The most commonly mutated gene in human tumours, including lung cancer, is p53 [6] . The most common mutations are missense mutations [10] causing an amino acid substitution, conformation change and accumulation in the cell nucleus, allowing identification using immunohistochemistry. Accumulation of its protein has shown significant correlation with regional lymph node metastasis, distant metastasis and pathological stage [4] .
This study attempts to assess the viability of nm23/ NDPK-A, c-erbB-2/p185, and p53 proteins as prognostic indicators in pulmonary adenocarcinoma using a large population of surgically resected tumours.
Materials and methods
Representative samples of primary lung adenocarcinomas were obtained from 162 patients treated surgically between 1980 and 1991. Sixty patients were female, 102 male, with a mean age at operation of 62.3 years (range: 36.5-87.6 years). Information on tumour and nodal status, clinical stage [13] and post-operative survival was obtained from the Grampian Pulmonary Resection Database.
Paraffin-embedded tissue sections were analysed using the streptavidin -biotin horseradish peroxidase method of immunohistochemistry [5] . The mouse monoclonal antibodies NCL-nm23 (Novocastra), NCL-CB11 (Novocastra) and Do7 (DAKO) were used in this study to identify the protein products of the NME1, c-erbB-2 and p53 genes, respectively. Sections were mounted on APES (3-aminopropyltriethoxysilane) coated slides, dewaxed, then rehydrated. Incubation in 1.5% hydrogen peroxide in methanol blocked endogenous peroxidase activity and microwave heating was used to optimise antigen unmasking. Optimal dilutions of the primary mouse monoclonal antibodies were applied and allowed to incubate for 1 h at room temperature (Do7-1 in 200 and CB11-1 in 100) or overnight at 4°C (nm23-1 in 200). Sections were developed in DAB (diaminobenzidine) solution with copper sulphate enhancement, counterstained with haematoxylin, dehydrated, cleared and mounted. Positive controls were included in each batch of sections and negative controls were performed for all sections.
Staining was scored by two observers blinded to tumour status and patient survival. The nm23/NDPK-A staining was scored as high level if more than 80% of cells demonstrated cytoplasmic positivity, and as low level if less than 80%. Intensity and distribution of nuclear p53 staining was scored: absent/weak/moderate/strong and focal (B 10% tumour cells positive), regional (10-50%), and diffuse ( \ 50%). An overall score was then assigned with high level as strong staining in any distribution or moderate in a regional or diffuse distribution, and all other patterns of staining as low level. The c-erbB-2/p185 membrane staining was scored as high level if more than 10% of cells were positive, and as low level if less than 10%.
Patients were allocated into four groups, those surviving 3 years and those less than 3 years post-operatively, those surviving 5 years or more and those less than 5 years. The 2 and the Mantel-Haenszel tests for linear association were applied when comparing protein expression with clinicopathological features and postoperative survival. The Microsoft 'SPSS' statistics package was used.
Results
Of the 162 primary lung adenocarcinomas, 77 (47.5%) demonstrated low-level nm23/NDPK-A staining, 101 (62.3%) showed high-level p53 staining and 30 (18.5%) high-level p185 expression. Assessment of p53 and NDPK-A/nm23 staining was uncomplicated; on the other hand, scoring of p185/c-erbB-2 staining was often difficult due to cytoplasmic positivity. When protein expression was compared with clinicopathological features, no significant associations were noted except in the case of p185 expression and nodal status. A significant difference (PB 0.05) was found between high-and low-level c-erbB-2/p185 membrane staining with respect to nodal status. Testing for linear association showed that high-level membrane staining was associated (PB 0.05) with higher nodal status. Of N0, N1 and N2 tumours, 10.3, 22.7 and 31.6%, respectively, showed high-level c-erbB-2 membrane expression.
Analysis of survival data revealed an actual 5-year survival of 31.1% (47/151) and 3-year survival of 45.1% (73/162). Significant differences were found between those patients surviving less than 5 years after resection compared with those surviving for 5 years or more with respect to nodal status (PB 0.05) and stage (PB0.
Discussion
Previous work on various tumours, including lung cancer, has suggested that a high level of nuclear p53, a high level of c-erbB-2/p185 in tumour cell membranes and a low level (loss of expression) of the supposed metastasis suppressor gene nm23 are each associated with a relatively poor prognosis. Our work has shown, on the numerically largest series so far studied, that in surgically resected pulmonary adenocarcinomas these markers do not predict post-operative survival.
From our assessment of patient survival with respect to stage, N status and T status, stage and nodal status showed the expected influence. No significant difference was found between the three T values. This, in itself, was unexpected, as it is generally accepted that T status is a predictor of patient prognosis. From this finding it could be deduced that nodal status is a more important determining factor in making stage the strong predictor of patient survival, as is accepted by clinicians and shown in this study.
Immunohistochemistry has been used extensively for the investigation of gene expression in neoplasia and has the basic advantage that it targets protein, the functional endpoint of gene transcription and translation, and allows visualisation of protein in individual cells. Errors may occur, however, since histology examines only a small sample of the tumour. This may be particularly relevant to the investigation of NDPK-A/ nm23.
Some degree of loss of NDPK-A expression, noted as low-level staining with less than 80% of tumour cells positive, was demonstrated in 47.5% of tumours. It could be argued that finding a single negative cell in a tissue section should be considered as loss of nm23 expression. Though this seems to have been done in a study on breast cancer [16] , it was not easily applied and an arbitrary value of less than 80% of cells staining positive was regarded as loss of expression.
The fact that our study found no correlation between the level of NDPK-A expression and nodal status, stage and post-operative survival would not support the metastasis suppressor theory and suggests that the level of NDPK-A expression in a primary tumour cannot be used as a prognostic indicator in lung adenocarcinoma. This appears to support the findings of a previous study [3] . Direct comparisons are difficult, however, due to differences in scoring systems and the specificities of the antibodies used. To ascertain whether nm23-H1 expression at RNA or protein level can be used as a prognostic indicator in malignancy will require investigations using specific, standardised laboratory techniques and scoring systems, with populations large enough to be recognisably informative.
Recently, the validity of the use of immunohistochemistry for investigation of p53 mutation has been questioned [20] . Detection of p53 depends on stabilisation induced by missense mutation allowing nuclear accumulation of abnormal protein. It is now accepted that accumulation of p53 can occur by mechanisms other than mutation [2] . The fact that all but 11 of the 162 cases were positive to some extent for p53 protein as recognised by Do7 may imply that the detection threshold has been lowered.
Of the 162 cases of primary lung adenocarcinoma, 101 (62.3%) exhibited high-level staining with Do7 for p53 protein. This compares with values found in the literature of around 40% [4, 19] . As previously mentioned, the use of different antibodies, antigen retrieval mechanisms and scoring systems makes useful comparisons between studies difficult. In addition, most of the work involving p53 and lung adenocarcinoma has been done in the context of non-small-cell lung cancer which cannot be directly related to a study concerning only adenocarcinoma.
The fact that 62.3% of the study cases demonstrated high-level positivity for p53 protein supports the hypothesis that disruption of normal p53 function, whether by mutation or otherwise, is an important, possibly a fundamental event in the development or progression of malignancy. Staining of normal lung tissue was not seen.
In a study of 88 primary lung cancers, p53 expression in adenocarcinoma was significantly associated with aggressive pathological features and a poorer prognosis [4] . The results of our investigation of 162 cases of adenocarcinoma would not support this view. No difference was found between high-or low-level p53 staining with respect to stage, nodal status or tumour status.
Again no significant difference was found between those cases exhibiting high-level and those with lowlevel Do7 staining for p53 protein and post-operative survival. This supports the findings of a smaller study which also found no difference between immunopositivity and negativity with respect to patient survival in lung adenocarcinoma [12] . It can be concluded, therefore, that p53 protein expression as demonstrated by the techniques previously described cannot be used as a prognostic indicator in lung adenocarcinoma.
High-level membrane staining was found in 18.5% of our study population. This compares with 38 and 28% [7, 18] in previous studies on lung adenocarcinoma. These differences could be a function of different scoring systems and antibodies used. In addition, CB11 has been shown to have a fairly high rate of false negativity [14] .
A statistically significant association was just reached (P= 0.049) between p185 expression and nodal status, such that p185 expression in the primary tumours correlated with advanced nodal disease. This could mean that the expression of p185 confers a more aggressive phenotype which is manifest in a greater propensity to spread either by direct invasion or by metastasis. Overexpression of p185 in in vitro models can result in increased metastatic potential. It is thought that p185 promotes important steps of the invasion process [21] . This finding would support the role of p185 as an inducer of enhanced metastatic potential. However, in our study, no association was demonstrated with T status, stage or post-operative survival.
Earlier studies on p185 expression in lung adenocarcinoma have found a significant association with shortened survival [7, 8, 18] . The results of this study would not support this relationship. We conclude that p185 expression in the primary tumours cannot be used as an independent indicator of prognosis in lung adenocarcinoma.
This study used a large population with carefully standardised laboratory techniques and scoring systems which attempted to take into consideration the proposed biological properties of the proteins. From the results obtained, we have shown that nm23/NDPK-A, c-erbB-2/p185 and p53 cannot be used as prognostic indicators in pulmonary adenocarcinoma. Dr D. Dougenis (Patras, Greece): I would like to congratulate you on your excellent presentation. I wonder why you chose to investigate only the adenocarcinomas, why you did not include the squamous lung carcinomas as well? As a matter of fact, in a study of ours looking at the expression of p53 and c-erbB-2 in NSCLC, we came up with the same conclusions regarding their prognostic significance.
Dr M. MacKinnon: The reason we chose adenocarcinoma was because it was a reasonably manageable size of population to deal with; we had 162 cases. In the entire database we actually have over 700 cases, which, with a year of research I was doing, was not practicable, but in the future I have no doubt that other histological types will be analysed.
Dr M. Ribet (Lille, France): Congratulations for a nice demonstration. There was something I did not grasp quite well. You studied the prognosis of your tumours according to the stage, which is quite logical. Then you studied the incidence of your proteins considering the whole population. Now, would it not be more logical to study that stage by stage, to break down the population stage by stage in a prospective way? Dr M. MacKinnon: In answer to the first part, the stages were examined individually as well as retrospectively, and as regards prospectively, that is another study which may well be done in the future.
Dr A. End (Vienna, Austria): Are you able to determine the p53 on paraffin sections or do you need frozen material? Dr M. MacKinnon: The antibody we were using was DAKO Do7, which can be used on paraffin sections and gives good results, as you may agree from the slide I showed; most of the staining produced by this antibody for p53 was excellent throughout the study and it was all done on paraffin sections.
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